Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE): a Randomized, Double-Blind, Placebo-Controlled Trial

NCT07859150 is registered in ClinicalTrials.gov with General Committee of Teaching Hospitals and Institutes, Egypt as lead sponsor.

NCT NCT07859150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07859150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE): a Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
April 30, 2029
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

morbid obesity